First-line maintenance immunotherapy in advanced urothelial cancers: Practice changing implications of the JAVELIN bladder 100 trial Kumaraswamy Santosh
Number of times
this article was viewed
1114
Number of times
this article has been printed from the site
36
Number of times
this article was emailed to others
Article
Access Statistics
